Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Voruz, Sophie, Blum, Sabine, de Leval, Laurence, Schoumans, Jacqueline, Solly, Françoise, Spertini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686620/
https://www.ncbi.nlm.nih.gov/pubmed/34930453
http://dx.doi.org/10.1186/s40364-021-00343-3
_version_ 1784618052375019520
author Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Françoise
Spertini, Olivier
author_facet Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Françoise
Spertini, Olivier
author_sort Voruz, Sophie
collection PubMed
description Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00343-3.
format Online
Article
Text
id pubmed-8686620
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86866202021-12-21 Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript Voruz, Sophie Blum, Sabine de Leval, Laurence Schoumans, Jacqueline Solly, Françoise Spertini, Olivier Biomark Res Letter to the Editor Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00343-3. BioMed Central 2021-12-20 /pmc/articles/PMC8686620/ /pubmed/34930453 http://dx.doi.org/10.1186/s40364-021-00343-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Françoise
Spertini, Olivier
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title_full Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title_fullStr Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title_full_unstemmed Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title_short Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
title_sort daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory cd19, cd20, and cd22 negative acute b lymphoblastic leukemia with kmt2a-aff1 transcript
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686620/
https://www.ncbi.nlm.nih.gov/pubmed/34930453
http://dx.doi.org/10.1186/s40364-021-00343-3
work_keys_str_mv AT voruzsophie daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript
AT blumsabine daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript
AT delevallaurence daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript
AT schoumansjacqueline daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript
AT sollyfrancoise daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript
AT spertiniolivier daratumumabandvenetoclaxincombinationwithchemotherapyprovidesustainedmolecularremissioninrelapsedrefractorycd19cd20andcd22negativeacuteblymphoblasticleukemiawithkmt2aaff1transcript

Ejemplares similares